Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Leases (2019 - 2024)

KalVista Pharmaceuticals' Operating Leases history spans 5 years, with the latest figure at $4.4 million for Q4 2024.

  • For Q4 2024, Operating Leases changed N/A year-over-year to $4.4 million; the TTM value through Dec 2024 reached $4.4 million, changed N/A, while the annual FY2024 figure was $6.0 million, N/A changed from the prior year.
  • Operating Leases for Q4 2024 was $4.4 million at KalVista Pharmaceuticals, up from $4.3 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.9 million in Q3 2023 and bottomed at $926000.0 in Q1 2020.
  • The 4-year median for Operating Leases is $4.4 million (2024), against an average of $3.7 million.
  • The largest annual shift saw Operating Leases increased 21.27% in 2021 before it crashed 33.73% in 2024.
  • A 4-year view of Operating Leases shows it stood at $932000.0 in 2020, then rose by 20.49% to $1.1 million in 2021, then soared by 482.9% to $6.5 million in 2023, then crashed by 32.22% to $4.4 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Operating Leases are $4.4 million (Q4 2024), $4.3 million (Q4 2024), and $5.0 million (Q3 2024).